Clinical trials: Fibrotic Interstitial Lung Disease
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Interstitial Lung Disease (ILD)
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development…
- Trial name
- NCT06655090
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Dai Huaping
Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF)
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung…
- Conditions
- Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- NCT07466420
- Testing
- Quercetin (dietary supplement), Usual treatment
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Katerina M. Antoniou
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis
Purpose: To demonstrate the safety and efficacy of autologous Lung Spheroid Stem Cells (LSCs) administered by intravenous infusion in patients with idiopathic pulmonary fibrosis Progressive Fibrotic Interstitial Lung Disease.
- Trial name
- HALT-IPF (NCT04262167)
- Testing
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Hypertension, Interstitial Lung Disease
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
Over time, patients with fibrosing or interstitial lung disease (ILD) can develop high lung blood pressures (pulmonary hypertension), and this is associated with poorer prognosis and survival.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia
- Trial name
- B-PHIT (NCT00637065)
- Testing
- Bosentan
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Hypersensitivity Pneumonitis, Extrinsic Allergic Alveolitis
Pulmonary Rehabilitation in Patients With Chronic Fibrotic Hypersensitivity Pneumonitis
The aim is to evaluate exercise capacity, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, physical activity level, quality of life, fatigue, dyspnea, anxiety, depression and…
- Trial name
- NCT04561479
- Testing
- Pulmonary Rehabilitation, Alternative Exercises
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Lung Diseases, Interstitial, Fibrosis Lung
Research of Burden of Interstititial Lung Diseases in Turkey
The aim of our study is to investigate the etiological distribution of ILD, epidemiological characteristics of ILD cases such as age, gender, geography, smoking, occupation, economic status, education, and comorbidities.
- Trial name
- RBILD (NCT03995654)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Karadeniz Technical University
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Interstitial Lung Disease
Specialist Dietetic Intervention in Malnourished Patients with Fibrotic ILD: a Randomised Controlled Pilot Trial
Malnutrition occurs when the body receives too few nutrients, resulting in health problems such as weight loss. The consequences of malnutrition are worrying as they include lung failure, infection, and pressure ulcers.
- Trial name
- DT-ILD (NCT06016959)
- Testing
- Dietetic intervention
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Fibrotic Interstitial Lung Disease
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
The fibrotic interstitial lung diseases (fILD) are characterised by lung scarring, distressing breathlessness and poor health-related quality of life.
- Trial name
- PFOX (NCT03737409)
- Testing
- Ambulatory Oxygen Therapy
- Where
- Australia
- Volunteers
- 116 people
- Sponsor
- Monash University
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Usual Interstitial Pneumonia, Nonspecific Interstitial Pneumonia
Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias
The diagnosis of idiopathic interstitial pneumonia (IIP) is based on computed tomography (CT) imaging, whereas lung function studies are used for staging and follow up.
- Trial name
- Dm&Vc (NCT02596841)
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea
FIBRotic Interstitial Lung Disease and Nocturnal OXygen
Home sleep studies - which allow the measurement of breathing while the person sleeps - will be performed on patients with fibrotic interstitial lung disease attending two of the UK's largest respiratory medicine services.The…
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Sleep Disturbance, Sleep Hypoventilation
- Trial name
- FIBRINOX (NCT04586946)
- Where
- 2 sites in United Kingdom
- Volunteers
- 102 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Fibrotic Interstitial Lung Disease
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath…
- Trial name
- NCT06053164
- Testing
- Exertional Oxygen, Education and Support
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of Alberta
Fibrotic Interstitial Lung Disease
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early antifibrotic therapy for f-ILD
- Trial name
- NCT07141810
- Testing
- Antifibrotic drugs (nidanib or pirfenidone)
- Volunteers
- 104 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Diseases, Interstitial
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
The planned study is a prospective cohort interventional study in IPF and PF-ILD patients after initiating anti-fibrotic therapy and pulmonary rehabilitation.
- Trial name
- Actigraphy (NCT05866198)
- Testing
- Actigraph CP Insight Watch
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of South Florida
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypersensitivity Pneumonitis
"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
Hypersensitivity Pneumonitis (HP) is an immune-mediated disease that manifests as interstitial lung disease after exposure to an inhaled antigen, often unidentified. HP can be classified as non-fibrotic or fibrotic HP.
- Trial name
- RUBY (NCT07210008)
- Testing
- Prednisolone
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris